# Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children

> **NCT03826901** · PHASE1 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 46 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** delgocitinib

## Key facts

- **NCT ID:** NCT03826901
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-20
- **Primary completion:** 2021-10-29
- **Final completion:** 2021-10-29
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2025-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03826901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03826901, "Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03826901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*